Novocure announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program. The program is intended to support both preclinical studies and clinical trials with TTFields, electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. To enable novel preclinical research, Novocure will provide Stanford Medicine investigators with its portfolio of proprietary inovitro, inovitro Live and inovivo TTFields preclinical systems which allows for exploring a vast range of research questions, starting from the fundamental physical mode of action all the way to most complex systemic biological outcomes. In addition, Novocure will provide devices for clinical studies.

At present, Stanford Medicine is a site for four clinical studies of TTFields therapy. This includes TRIDENT, a Novocure-sponsored multi-center study of TTFields therapy given concomitantly with radiation therapy and temperatureozolomide in newly diagnosed glioblastoma (GBM) patients, in which Stanford University Cancer Institute is one of 132 participating study centers. Investigator-sponsored trials at Stanford include multiple investigational uses, including a study of TTFields Therapy for children with high-grade glioma or ependymoma and TTFields therapy for children with diffuse intrinsic pontine glioma, a study of TTField's therapy with hypofractionated chemoradiotherapy in newly diagnosed GBM, and a study of TTFielding Fields therapy with bevacizumab in treating patients with recurrent or progressive Grade 2 or 3 meningioma.

In addition, Stanford is home to a preclinical study of the efficacy of TTFields in medulloblastoma.